Novavax Inc (NASDAQ:NVAX)
| 182.70 Delayed Data As of Aug 02 |  +3.39 / +1.89%Today’s Change | 76.59 Today|||52-Week Range 331.68 | +63.84% Year-to-Date |
Latest NVAX News | Press Releases
Today’s Trading
| Previous close | 179.33 |
| Today’s open | 183.82 |
| Day’s range | 177.17 - 186.50 |
| Volume | 2,743,763 |
| Average volume (3 months) | 3,856,321 |
| Market cap | $13.3B |
Data as of 4:00pm ET, 08/02/2021
Growth & Valuation
| Earnings growth (last year) | -31.99% |
| Earnings growth (this year) | +11.66% |
| Earnings growth (next 5 years) | +2.00% |
| Revenue growth (last year) | +2,448.48% |
| P/E ratio | NM |
| Price/Sales | 13.49 |
| Price/Book | 20.28 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ZLABZai Lab Ltd | +0.32 | +0.22% |
| BMRNBiomarin Pharmaceuti... | +0.68 | +0.89% |
| NTLAIntellia Therapeutic... | -5.28 | -3.72% |
| CRSPCRISPR Therapeutics ... | +1.32 | +1.09% |
Data as of 4:00pm ET, 08/02/2021
Financials
| Next reporting date | August 6, 2021 |
| EPS forecast (this quarter) | -$3.63 |
| Annual revenue (last year) | $475.6M |
| Annual profit (last year) | -$418.3M |
| Net profit margin | -87.94% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Gaithersburg, Maryland |
Forecasts
